Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Open-label, Single-arm, Dose-escalation Clinical Study Evaluating the Safety and Efficacy of ET190L1 ARTEMIS™ (Anti-CD19-ARTEMIS™) in Relapsed, Refractory B Cell Lymphoma

Trial Profile

Phase 1, Open-label, Single-arm, Dose-escalation Clinical Study Evaluating the Safety and Efficacy of ET190L1 ARTEMIS™ (Anti-CD19-ARTEMIS™) in Relapsed, Refractory B Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs ET-190 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Proof of concept
  • Sponsors Eureka Therapeutics
  • Most Recent Events

    • 04 Dec 2018 Interim results (Data cut off 18 July 2018, n=21) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 05 Jun 2018 Results (n=12, as of 23 Jan 2018) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2018 According to an Eureka Therapeutics media release, As of May 30, 2018, 21 adult patients with CD19-positive (CD19+) r/r B-cell lymphoma, have received autologous ET190L1-ARTEMIS T-cells, and 17 subjects have completed the 1 month safety and efficacy assessment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top